Leronilmab is a receptor entry inhibitor and an immunomodulator based on interaction with T-cells, mitigation of the immune response could be called immunosuppression of a hyperimmune response The ultimate point of the mitigation is the macrophage,

Lenzulimab also mAB works by neutalizes GM CSF which is in the plasma, thereby mitigating the vicious macrophage cyle. I think the science is solid, and I mentioned on a previous post several days they were awarded funding through the BET program, an honor.